Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$87.89 USD
+0.86 (0.99%)
Updated May 30, 2024 04:00 PM ET
After-Market: $87.92 +0.03 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Price, Consensus and EPS Surprise
EW 87.89 +0.86(0.99%)
Will EW be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for EW based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EW
HOLX or EW: Which Is the Better Value Stock Right Now?
Here's Why You Should Retain Edward Lifesciences (EW) for Now
EW: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights Salesforce, BP, The Southern, PayPal and Edwards Lifesciences
Top Analyst Reports for Salesforce, BP & Southern Co.
ALC vs. EW: Which Stock Is the Better Value Option?
Other News for EW
PayPal upgraded, UiPath downgraded: Wall Street's top analyst calls
What Analysts Are Saying About Edwards Lifesciences Stock
If You Invested $100 In This Stock 20 Years Ago, You Would Have $2,900 Today
Edwards Lifesciences initiated with bullish view at Goldman Sachs, here's why
Buy Rating Affirmed for Edwards Lifesciences on Growth and Market Positioning Prospects